About Organogenesis
Organogenesis (NASDAQ:ORGO) specializes in regenerative medicine, focusing on the development, manufacturing, and commercialization of solutions for the advanced wound care, surgical, and sports medicine markets. Its portfolio encompasses a wide range of products designed to facilitate the body's own healing process. The company is dedicated to improving patient outcomes and reducing healthcare costs through its innovative therapies. With a strong commitment to research and development, Organogenesis aims to expand its product offerings and explore new applications for its regenerative medicine technologies. By continuously advancing the field of regenerative medicine, Organogenesis seeks to address unmet medical needs and enhance the quality of life for patients around the world.
Snapshot
Operations
Products and/or services of Organogenesis
- Apligraf, a bio-engineered skin substitute for treating venous leg ulcers and diabetic foot ulcers.
- PuraPly Antimicrobial (AM), which manages bioburden in wounds and supports healing.
- Affinity, a porcine-derived skin graft used in wound management for non-healing wounds.
- NuShield, a placental-derived tissue product that aids in the management of surgical wounds.
- ReNu, a cryopreserved amniotic suspension allograft for the management of symptoms associated with knee osteoarthritis.
- BioVance, an amniotic membrane allograft that supports wound closure in various types of wounds.
Organogenesis executive team
- Mr. Gary S. Gillheeney Sr.President, CEO, Chair of the Board
- Mr. David C. FranciscoChief Financial Officer
- Mr. Patrick BilboChief Operating Officer
- Ms. Lori H. Freedman B.A., Esq., J.D.Chief Administrative & Legal Officer
- Mr. Brian GrowChief Commercial Officer
- Mr. William R. Kolb CPASecretary
- Mr. Robert CavorsiVice President of Strategy